A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

The world-first gene therapy (BE-CAR7) uses base-edited immune cells to treat previously untreatable T-cell leukemia and help patients achieve remission, offering new hope for families facing this aggressive cancer. Base-editing is an advanced version of CRISPR technology, that can precisely change single letters of DNA code inside living cells.

In 2022, researchers from GOSH and UCL delivered the world’s first treatment made using “base-editing” to a 13-year-old girl from Leicester, Alyssa.